Clinical trial · Interventional
Effect of Metformin on Decrement in Levothyroxin Dose Required for Thyroid Stimulating Hormone (TSH) Suppression in Patients With Differentiated Thyroid Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Differentiated thyroid cancer is the most common neoplasm of endocrine system. After surgery and radioiodine treatment, thyroid stimulating hormone (TSH) suppression is the main goal which is achieved with levothyroxine treatment. Levothyroxine causes increased thyroid hormones which can have negative impact on bone and cardiovascular system. Anecdotal reports have shown that metformin can induce TSH suppression without change in T3 and T4 concentration. The purpose of this study was to prescribe metformin as additional drug to levothyroxin in order to decrease levothyroxine dosage.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Neoplasm of Thyroid Stage I | Malignant Thyroid Gland Neoplasm | CURATED_BROADER | 0.78 |
| Malignant Neoplasm of Thyroid Stage II | Malignant Thyroid Gland Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Metformin | Drug | Metformin | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- metformin
- description
- patients who receive metformin in addition to levothyroxine
- interventionNames
- Drug: Metformin
- type
- PLACEBO_COMPARATOR
- label
- levothyroxine
- description
- patients who receive only levothyroxine
- interventionNames
- Drug: Metformin
Primary outcomes (1)
- measure
- TSH
- timeFrame
- 3 months
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * papillary or follicular thyroid cancer * stage 1 or 2 according to TNM system version 6 * surgery and radioiodine treatment * levothyroxine suppression treatment Exclusion Criteria: * cardiopulmonary failure * liver failure * renal failure * pregnancy * drugs (colestyramin, sucralfate, phenobarbital, phenytoin, carbamazepin, rifampin, amiodarone, chloroquin, androgens, sertraline, frusemide, heparin)
References
Publications (0)
Data not yet available